QRONO, INC

Basic Information

QRONO, INC.
4551 Forbes Ave
PITTSBURGH, PA, 15213-3524

http://www.qrono.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 055292329
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 2


  1. Computationally designed adjuvant platform enhancing dengue vaccine immunogenicity

    Amount: $99,999.00

    Dengue fever incidence has grown exponentially over the past 50 years and now causes disease in nearly 100 million people annually. Vaccination offers the most effective method of protecting at-risk i ...

    SBIR Phase I 2015 Department of Defense Army
  2. Development of a long-acting, injectable controlled release butyrylcholinesterase formulation using predictive modeling.

    Amount: $998,670.00

    Elevated levels of human butyrylcholinesterase (hBuChE) confer protection from chemical warfare nerve agents and other organophosphorous chemicals. As a prophylactic, the key to enabling this protect ...

    SBIR Phase II 2014 Department of Defense Office for Chemical and Biological Defense
  3. Title: Failed tubulin inhibitor reformulated as localized adjuvant therapy for head and neck cancer POP: 09/12/2014-06/11/2015

    Amount: $223,412.00

    Qrono's long-term oncology goal is to revolutionize cancer treatment with safer, more efficacious chemotherapy formulations. Qrono has created a new drug delivery platform by mathematically optim ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Development of a long-acting, injectable controlled release butyrylcholinesterase formulation using predictive modeling.

    Amount: $99,575.00

    Elevated levels of human butyrylcholinesterase (BuChE) confer protection from chemical warfare nerve agents and other organophosphorous chemicals. As a prophylactic, the key to enabling this protecti ...

    SBIR Phase I 2013 Department of Defense Office for Chemical and Biological Defense
  5. A New In Silico Design Platform for Building Custom Controlled Release Systems

    Amount: $256,217.00

    DESCRIPTION (provided by applicant): Controlled release formulations can improve patient adherence and drug safety or even enable new types of basic medical research. The key to realizing these benefi ...

    STTR Phase I 2013 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government